Indication · General & Plastic Surgery
Skin cancer
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
36
Cleared or approved since 2000
PMA and De Novo
3
Higher-risk or first-of-kind devices
Breakthrough devices
1
Authorized through June 30, 2026
Recruiting device trials
41
242 device trials in all
Breakthrough-designated devices
- DermaSensorDermasensor, Inc. · 2024
Devices
36 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Melafind
Strata Skin Sciences, Inc. · PMA · Optical Diagnostic Device For Melanoma Detection · newest 2016 · 6 decisions
35 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Skin Cancer Detection in Primary Care With and Without DermaSensorPivotal-lookingNot yet recruiting
DermaSensor, Inc.Not on our public-company list
NCT07940036 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 2028
Device: DermaSensor · For: Skin Cancer; Basal Cell Cancer; Squamous Cell Carcinoma and 4 more
Sites: St Louis, Missouri
241 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on melanoma across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.